J&J Profit Beats Estimates as Pharma Sales Edge Out Street [BNN Bloomberg (Canada)]
Kenvue Inc. (KVUE)
Company Research
Source: BNN Bloomberg
Adjusted quarterly profit was $2.71 a share, J&J said Tuesday in a statement, compared with analysts' average estimate of $2.65. Sales of medicines were $13.6 billion, slightly outpacing the average estimate of analysts surveyed by Bloomberg, while overall revenue matched Street projections. J&J split off its consumer-health unit that makes Tylenol and Listerine last year as Kenvue Inc. in order to focus on higher-margin sales of drugs and medical devices. The company still faces declining revenues from its top-selling psoriasis drug Stelara next year and is looking to products like prostate-cancer therapy Erleada and Tremfya for psoriasis to fill the gap. New Brunswick, New Jersey-based J&J has also been investing in medical devices, agreeing earlier this month to buy Shockwave Medical Inc. for $13.1 billion. J&J also closed the purchase of Abiomed Inc., a maker of heart devices, at the end of 2022 for $16.6 billion. The company also slightly narrowed its adjusted profit guida
Show less
Read more
Impact Snapshot
Event Time:
KVUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KVUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KVUE alerts
High impacting Kenvue Inc. news events
Weekly update
A roundup of the hottest topics
KVUE
News
- Kenvue Declares Quarterly Cash DividendBusiness Wire
- Zimbabwe Recalls Tainted J&J's Cough Syrup Sold in Six African Nations [BNN Bloomberg (Canada)]BNN Bloomberg
- J&J's Tainted Cough Syrup Was Sold in Six African Countries [BNN Bloomberg (Canada)]BNN Bloomberg
- Kenvue Inc. (NYSE: KVUE) is now covered by analysts at Sanford C. Bernstein. They set an "underperform" rating and a $18.00 price target on the stock.MarketBeat
- Why Kenvue (KVUE) Could Beat Earnings Estimates Again [Yahoo! Finance]Yahoo! Finance
KVUE
Earnings
- 2/8/24 - Beat
KVUE
Sec Filings
- 4/10/24 - Form ARS
- 4/10/24 - Form DEFA14A
- 4/10/24 - Form DEF
- KVUE's page on the SEC website